已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Therapeutic effect of Zhibitai combined with atorvastatin in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of hypersensitive C-reactive protein

医学 阿托伐他汀 高脂血症 内科学 甘油三酯 C反应蛋白 冠心病 胃肠病学 血脂 入射(几何) 不利影响 胆固醇 高密度脂蛋白 冠状动脉疾病 急性冠脉综合征 心脏病学 内分泌学 炎症 心肌梗塞 糖尿病 物理 光学
作者
Tong Lu,Bin Tan,Tingting Deng,Yongping Hua,Gang Xu
出处
期刊:Chinese Journal of Primary Medicine and Pharmacy 卷期号:26 (24): 3022-3025
标识
DOI:10.3760/cma.j.issn.1008-6706.2019.24.020
摘要

Objective To study the effect of atorvastatin combined with Zhibitai in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of high-sensitivity C-reactive protein(hsCRP). Methods A total of 136 patients with coronary heart disease and hyperlipidemia admitted to the Third People's Hospital of Jingdezhen from September 2016 to September 1818 were randomly divided into control group and combination group using stochastic comprehensive balance method, with 68 cases in each group.The control group was treated with atorvastatin and the combination group was treated with lipidine plus atorvastatin. The patient's treatment effect, including the blood lipid compliance rate and the occurrence of adverse reactions during the treatment were observed, as well as the patient's pre-and post-treatment triglyceride(TG), 12h serum total cholesterol(TC), high-density lipoprotein-cholesterol(HDL-C), low density lipoprotein-cholesterol(LDL-C)and high-sensitivity C-reactive protein(hsCRP)and other indicators were measured. Results (1)The blood lipid compliance rate(89.86%) in the combined group was higher than that in the control group(59.70%), the difference was statistically significant(χ2=14.915, P=0.000). (2)The incidence of adverse reactions in the combined group(1.45%) was lower than that in the control group(17.91%), the difference was statistically significant(χ2=8.836, P=0.003). (3)The results showed that the TC, TG, LDL-C, hsCRP and other indicators of the combined group were lower than those of the control group and before treatment, while the HDL-C index of the combined groupwas higher than that of the control group and before treatment, the differences were statistically significant(t=20.800, 4.903, 11.657, 4.346, 6.262, P=0.000, 0.000, 0.000, 0.000, 0.000). Conclusion Zhibitai combined with atorvastatin in the treatment of coronary heart disease patients with hyperlipidemia has remarkable effect.It can accurately control TC, TG, LDL-C, HDL-C and hsCRP, improve blood lipid control rate. Key words: Coronary artery disease; Hyperlipidemias; Lipoproteins, HDL; Cholesterol, LDL; C-Reactive protein; Triglycerides; Adverse reactions; Zhibitai; Atorvastatin
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
黑森林完成签到,获得积分10
刚刚
王某完成签到 ,获得积分10
1秒前
大道希言完成签到 ,获得积分10
2秒前
牛牛完成签到 ,获得积分10
8秒前
周萌完成签到 ,获得积分10
12秒前
14秒前
CompJIN完成签到,获得积分10
16秒前
17秒前
33发布了新的文献求助10
19秒前
20秒前
满意的又蓝完成签到,获得积分10
21秒前
该睡觉啦发布了新的文献求助10
22秒前
22秒前
解语花发布了新的文献求助50
25秒前
stark完成签到,获得积分10
25秒前
小张完成签到 ,获得积分10
27秒前
壮观的谷冬完成签到 ,获得积分0
30秒前
33秒前
CodeCraft应助小巧健柏采纳,获得10
35秒前
36秒前
斯文败类应助该睡觉啦采纳,获得10
38秒前
linkman发布了新的文献求助10
39秒前
你嵙这个期刊没买完成签到 ,获得积分10
40秒前
解语花完成签到,获得积分10
40秒前
44秒前
47秒前
明朗完成签到 ,获得积分10
48秒前
LYL完成签到,获得积分10
49秒前
bkagyin应助senlin采纳,获得10
50秒前
52秒前
孤独的以菱完成签到 ,获得积分20
54秒前
香蕉觅云应助Maryamgvl采纳,获得10
55秒前
直率以蓝完成签到,获得积分20
56秒前
1分钟前
科研通AI2S应助诺一44采纳,获得10
1分钟前
morena发布了新的文献求助10
1分钟前
Hcc完成签到 ,获得积分10
1分钟前
清新的宛丝完成签到,获得积分10
1分钟前
你好完成签到 ,获得积分20
1分钟前
诺一44发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Zeolites: From Fundamentals to Emerging Applications 1500
International Encyclopedia of Business Management 1000
Encyclopedia of Materials: Plastics and Polymers 1000
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
Hidden Generalizations Phonological Opacity in Optimality Theory 1000
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4934907
求助须知:如何正确求助?哪些是违规求助? 4202605
关于积分的说明 13058103
捐赠科研通 3977151
什么是DOI,文献DOI怎么找? 2179393
邀请新用户注册赠送积分活动 1195525
关于科研通互助平台的介绍 1106915